Bothrops snakebite on the head: case report and review of the literature.
A previously healthy, 21-year-old female was admitted 5 h after being bitten in the occipital region by a pitviper presumed to be Bothrops jararaca. Physical examination revealed marked cranial and facial oedema extending to the neck and dorsum, bilateral eyelid ecchymosis, and local conjunctival and gingival bleeding. The patient was alert and complained of mild, local pain and nausea. There were no signs of neurological involvement. The main laboratory findings on admission included incoagulable blood, a platelet count of 4000/microl, and an ELISA-estimated serum venom concentration of 62.6 ng/ml. Sequential serum creatinine, urea nitrogen, sodium and potassium concentrations were normal. The case was classified as severe and, after the intravenous administration of ranitidine, chlorpheniramine and hydrocortisone, the intravenous infusion of 12 vials of undiluted bothropic equine antivenom [F(ab)(2); 10 ml/vial] was initiated. The antivenom infusion was halted after 10 vials because the patient developed a severe early reaction, although this was successfully treated with subcutaneous adrenaline and intravenous hydrocortisone. Platelet replacement (seven units) was performed and 24 h after the antivenom infusion, normal results in blood-coagulation tests and an increase in the platelet count (to 100,000/microl) were observed. No circulating venom was detected in blood samples collected 6, 12, 24 or 48 h post-admission. The patient was discharged after 4 days, with clinical improvement and no signs of local infection, and subsequent follow-up revealed no sequelae.
Bucaretchi
F
F
Departamento de Pediatria, Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), CP 6111, 13083-970, Campinas, SP, Brazil. bucaret@fcm.unicamp.br
Hyslop
S
S
Mello
S M
SM
Vieira
R J
RJ
D000328:Adult; D000818:Animals; D000997:Antivenins / Q000009:adverse effects*; D017837:Bothrops; D003435:Crotalid Venoms / Q000506:poisoning*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D012909:Snake Bites / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000997:Antivenins; D003435:Crotalid Venoms; D007155:Immunologic Factors